MedTrace Logo

Atorvastatin for HAART Suboptimal Responders

NCT01766076 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-05-21

Study results available
· View outcomes & findings →

Summary

We hypothesise that atorvastatin changes immune activation among HAART-treated adults with suboptimal cluster cell differentiation 4 (CD4) recovery by 25%

Conditions

  • Acquired Immune Deficiency Syndrome Virus

Interventions

OTHER

atorvastatin, Lipitor®

PBMC collected for immune activation assays using flowcytometry

DRUG

Placebo

PBMC collected for immune activation assays using flowcytometry

Sponsors & Collaborators

  • Vaccine and Gene Therapy Institute, Florida

    collaborator OTHER

  • Makerere University

    lead OTHER

Principal Investigators

  • Damalie Nakanjako, MD, PhD · Makerere University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-02-28
Completion
2014-03-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01766076 on ClinicalTrials.gov